New hope for lung cancer patients when first targeted therapy stops working
NCT ID NCT06652048
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a higher dose of the targeted drug furmonertinib, either alone or combined with chemotherapy, can help people with advanced EGFR-mutant non-small cell lung cancer whose first targeted treatment stopped working. About 60 participants will be randomly assigned to one of three groups: a higher dose of furmonertinib, an even higher dose, or furmonertinib plus standard chemotherapy. The goal is to see which approach delays cancer growth the longest.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Furmonertinib (a targeted cancer pill) and chemotherapy (pemetrexed plus carboplatin or cisplatin)
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer whose current targeted therapy has stopped working.
- What could go wrong
- This is a small, early-phase (Phase 2) study with only 60 participants, so results may not apply to everyone. Higher doses of furmonertinib may cause more side effects, and combining it with chemotherapy increases toxicity risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan university shanghai cancer center
RECRUITINGShanghai, Shanghai Municipality, 021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?